Molecular Templates, Inc.

Pipeline

A Pipeline of Differentiated Oncology Candidates

Engineered toxin bodies (ETBs) are differentiated biologic therapies with unique properties.  Single agent activity and tolerability have been observed with ETB therapy in heavily relapsed/refractory patients.

Program Partner Indication (Target) Preclinical Phase 1 Phase 2 Phase 3 Next Stage
MT-5111 Multiple - solid tumors (HER2)
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
TAK-169 Multiple Myeloma (CD38)
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
MT-6402 Multiple - solid tumors (PD-L1)
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
CTLA-4 Multiple – solid tumors (CTLA-4)
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
SLAMF-7 Multiple Myeloma (SLAMF-7)
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Completed
In-progress
Planning

MT-5111

2nd-Generation ETB Targeting HER2

MT-5111 is an ETB candidate that has been shown pre-clinically to bind and kill HER2 expressing cells in a way that is consistent with SLTA mediated cellular cytotoxicity. MT-5111 is designed to avoid competition with other HER2 targeted agents and overcome the mechanisms of tumor resistance to current HER2 targeted therapies. MT-5111 is currently in a first-in-human Phase 1 dose-escalation study of patients with HER2+ solid tumors.

View Candidate

TAK-169

2nd-Generation ETB Targeting CD38

TAK-169 is an ETB candidate that has been shown pre-clinically to bind and kill CD38 expressing cells in a way that is consistent with SLTA mediated cellular cytotoxicity. TAK-169 is currently in a first-in-human Phase 1 dose-escalation study of relapsed/refractory myeloma patients.

View Candidate

MT-6402

3rd-Generation ETB Targeting PD-L1

MT-6402 is an ETB candidate designed to induce potent anti-tumor effects via PD-L1 targeting through multiple mechanisms that may overcome the limitations of the PD-L1 antibodies. The IND for MT-6402 was accepted in January 2021 and a Phase 1 study of MT-6402 in PD-1/PD-L1 antibody relapsed/refractory patients is expected to be initiated in the first half of 2021.

View Candidate

ETBs are in development for other targets, including CTLA-4, SLAMF7 and CD45.